Achieve Life Sciences Inc Hares (NASDAQ:ACHV) Shorts Declined By 16.05% As Of Dec 8, 2018

Change of 16.05% for Achieve Life Sciences Inc Hares (NASDAQ:ACHV)’s short interest was reported. In December was announced ACHV’s total 296,500 short interest by FINRA. The 353,200 previous shares are down with 16.05%. With Average volume 56,900, ACHV’s previous position will take 5 days to recover. Achieve Life Sciences Inc Hares’s short interest float is 7.04%.

ACHV touched $1.45 during the last trading session after $0.03 change.Currently Achieve Life Sciences, Inc. is downtrending after 91.20% change in last December 8, 2017. ACHV has also 241,301 shares volume. ACHV underperformed the S&P 500 by 106.82%.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients.The firm is valued at $9.75 million. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer.Last it reported negative earnings.

For more Achieve Life Sciences, Inc. (NASDAQ:ACHV) news posted recently go to: Investorplace.com, Benzinga.com, Seekingalpha.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Achieve Life Sciences Stock Will Probably Tumble Further – Investorplace.com” posted on October 03, 2018, “10 Hottest Stocks From October 31, 2018 – Benzinga” on October 31, 2018, “Achieve Life Sciences expands partnership with the University of Bristol for Cytisine-based therapies – Seeking Alpha” with a publish date: January 24, 2018, “U.S. STOCKS ON THE MOVE-Under Armour, GE, Chegg, Cognex – Nasdaq” and the last “Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results, IPOs (Nov. 4-10) – Benzinga” with publication date: November 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.